Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (61-70 of 158) with videos related to

Pageof 16
Sort By:
Leukemia Research|December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsValeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Leukemia Research|April 7, 2007
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcomeSabine Knipp, Corinna Strupp, Norbert Gattermann, et al.
Mechanisms of Ageing and Development|August 24, 2007
Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cellsWolf C Prall, Akos Czibere, Marcus Jäger, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|December 15, 2025
[Feasibility of a virtual reality (VR)-supported mindfulness intervention for patients with cancer during chemotherapy]André Karger, Steffen Holsteg, Tanja N Fehm, et al.
Blood Cancer Journal|August 11, 2019
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patientsTobias Silzle, Sabine Blum, Esther Schuler, et al.
Cancer|June 15, 2007
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypesSabine Knipp, Barbara Hildebrand, Andrea Kündgen, et al.
Leukemia Research|July 9, 2010
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinionPierre Fenaux, David Bowen, Norbert Gattermann, et al.
European Journal of Haematology|June 25, 2009
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromesJudith Neukirchen, Sabine Blum, Andrea Kuendgen, et al.
Leukemia Research|October 7, 2019
Neut-X can be successfully used as diagnostic and prognostic tool in MDSAmelie Boquoi, Carmen Barthuber, Judith Strapatsas, et al.
British Journal of Haematology|January 10, 2006
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposalsUlrich Germing, Corinna Strupp, Andrea Kuendgen, et al.
Pageof 16

Showing results (61-70 of 158) with videos related to

Sort By:
Pageof 16
Leukemia Research|December 3, 2014
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsValeria Santini, Thomas Prebet, Pierre Fenaux, et al.
Leukemia Research|April 7, 2007
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcomeSabine Knipp, Corinna Strupp, Norbert Gattermann, et al.
Mechanisms of Ageing and Development|August 24, 2007
Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cellsWolf C Prall, Akos Czibere, Marcus Jäger, et al.
Psychotherapie, Psychosomatik, Medizinische Psychologie|December 15, 2025
[Feasibility of a virtual reality (VR)-supported mindfulness intervention for patients with cancer during chemotherapy]André Karger, Steffen Holsteg, Tanja N Fehm, et al.
Blood Cancer Journal|August 11, 2019
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patientsTobias Silzle, Sabine Blum, Esther Schuler, et al.
Cancer|June 15, 2007
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypesSabine Knipp, Barbara Hildebrand, Andrea Kündgen, et al.
Leukemia Research|July 9, 2010
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinionPierre Fenaux, David Bowen, Norbert Gattermann, et al.
European Journal of Haematology|June 25, 2009
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromesJudith Neukirchen, Sabine Blum, Andrea Kuendgen, et al.
Leukemia Research|October 7, 2019
Neut-X can be successfully used as diagnostic and prognostic tool in MDSAmelie Boquoi, Carmen Barthuber, Judith Strapatsas, et al.
British Journal of Haematology|January 10, 2006
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposalsUlrich Germing, Corinna Strupp, Andrea Kuendgen, et al.
Pageof 16